X
<

What Drove Eli Lilly in 3Q17?

PART:
1 2 3 4 5 6 7 8 9 10 11 12
Part 4
What Drove Eli Lilly in 3Q17? PART 4 OF 12

How Eli Lilly’s Endocrinology Drugs Are Performing

Humalog revenue trends

In 3Q17, Eli Lilly’s (LLY) Humalog generated revenues of $696.2 million, ~9% growth on year-over-year (or YoY) basis and 3% growth on a quarter-over-quarter basis. In 3Q17, in the US market and international markets, Humalog reported revenues of $414.9 million and $281.3 million, respectively, compared to $378.8 million and $262.0 million in 3Q17. Humalog reported revenues of $2.0 billion in the first nine months of 2017. Humalog competes with Novo Nordisk’s (NVO) Novolog.

How Eli Lilly’s Endocrinology Drugs Are Performing

Interested in IVV? Don't miss the next report.

Receive e-mail alerts for new research on IVV

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

Humatrope revenue trends

In 3Q17, Humatrope generated revenues of $81.2 million, ~12% growth on a YoY basis and 3% growth on a quarter-over-quarter basis. In 3Q17, in the US and international markets, Humatrope generated revenues of $39.7 million and $41.5 million, respectively, compared to $30.5 million and $42.2 million in 3Q16.

Humatrope reported revenues of $226.7 million in the first nine months of 2017. Eli Lilly’s Humatrope competes with Pfizer’s (PFE) Genotropin and Novo Nordisk’s Norditropin. In 3Q17, Pfizer’s Genotropin reported revenues of $136 million. In the first nine months of 2017, the drug earned revenues of around $375 million.

Humulin revenue trends

In 3Q17, Humulin generated revenues of $300.5 million, a ~7% decline on a YoY basis and a 16% decline on a quarter-over-quarter basis. In 3Q17, in the US and international markets, Humulin generated revenues of $203.0 million and $97.5 million, respectively, compared to $195.6 million and $126.4 million in 3Q16.

Humulin reported revenues of $972.8 million in the first nine months of 2017. Eli Lilly’s Humulin competes with Sanofi’s (SNY) Lantus, Novo Nordisk’s Levemir, and Novolog. In 3Q17, Levemir reported revenues of 3.1 billion Danish krone.

In October 2017, Eli Lilly announced its plans to invest $72 million for an insulin manufacturing project at one of the company’s manufacturing facilities in Indianapolis. The high demand for Humalog and Humulin primarily led the company to replace an existing insulin vial filing line with an upgraded state-of-the-art technology insulin pipeline.

The growth in sales of Eli Lilly’s Humalog and Humatrope could boost the iShares Core S&P 500 ETF (IVV). Eli Lilly makes up about ~0.32% of IVV’s total portfolio holding.

X

Please select a profession that best describes you: